



GRANULES

**REGISTERED OFFICE**

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, India.  
Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Date: January 24, 2023**

To,  
National Stock Exchange of India Limited  
BSE Limited  
NSE Symbol - Granules; BSE Code- 532482

**Dear Sir / Madam**

**Sub: Outcome of the Board meeting dated January 24, 2023.**  
**Ref: Regulations 30 and 33 of the Listing Regulations.**

Dear Sir,

The Board of Directors at their meeting has approved the unaudited financial results (Standalone & Consolidated) for the third quarter and nine months that ended on December 31, 2022, prepared under Indian Accounting Standards (Ind - AS).

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing the un-audited financial results (Standalone and Consolidated) of the Company for the third quarter and nine months that ended on December 31, 2022.

We also enclose a copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations and the press release.

The meeting of the Board of Directors of the Company commenced at 09.30 A.M and concluded at 01.30 P.M. This is for your information and record.

Thanking you,

**FOR GRANULES INDIA LIMITED**

**CHAITANYA TUMMALA**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Granules India Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Granules India Limited (the "Company") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



# S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. The comparative Ind AS financial information of the Company for the corresponding quarter and nine months ended December 31, 2021, included in these standalone Ind AS financial results, were reviewed by the predecessor auditor and the Standalone Ind AS financial statements of the Company for the year ended March 31, 2022, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those financial information on February 08, 2022 and May 18, 2022.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

*Navneet Kabra*

per Navneet Kabra

Partner

Membership No.: 102328



UDIN: 23102328BGSKR6449

Place: Hyderabad

Date: January 24, 2023



**GRANULES INDIA LIMITED**  
 Regd Office : 2nd Floor, 3rd Block, My Home Hub  
 Madhapur, Hyderabad 500 081  
 CIN:L24110TG1991PLC012471

**Statement of Standalone Un-Audited Results for the quarter and nine months ended December 31, 2022**


Rs in Lakhs

| Sl No. | Particulars   | Quarter ended      |                  |                  | Nine months ended  |                    | Year ended         |
|--------|---|--------------------|------------------|------------------|--------------------|--------------------|--------------------|
|        |   | 31-Dec-22          | 30-Sep-22        | 31-Dec-21        | 31-Dec-22          | 31-Dec-21          | 31-Mar-22          |
|        |   | Un-Audited         | Un-Audited       | Un-Audited       | Un-Audited         | Un-Audited         | Audited            |
|        | <b>Income</b>   |                    |                  |                  |                    |                    |                    |
| 1      | Revenue from operations   | 1,03,239.10        | 96,357.66        | 88,977.85        | 2,91,732.46        | 2,32,558.84        | 3,23,843.66        |
| 2      | Other income  | (92.81)            | 375.11           | 478.52           | 737.14             | 1,323.09           | 1,751.00           |
| 3      | <b>Total income (1+2)</b>   | <b>1,03,146.29</b> | <b>96,732.77</b> | <b>89,456.37</b> | <b>2,92,469.60</b> | <b>2,33,881.93</b> | <b>3,25,594.66</b> |
|        | <b>Expenses</b>   |                    |                  |                  |                    |                    |                    |
|        | (a) Cost of materials consumed                                    | 54,193.20          | 56,006.54        | 51,347.43        | 1,57,221.30        | 1,36,080.67        | 1,86,415.66        |
|        | (b) Changes in inventories of work in progress and finished goods | 1,808.27           | (2,246.11)       | (2,623.62)       | 3,016.60           | (8,910.30)         | (10,641.06)        |
|        | (c) Employee benefit expenses                                     | 8,304.77           | 8,051.44         | 7,183.95         | 24,041.43          | 20,734.85          | 28,279.90          |
|        | (d) Finance costs   | 1,175.57           | 836.05           | 295.59           | 2,455.51           | 1,235.14           | 1,635.23           |
|        | (e) Depreciation and amortisation expense                         | 3,832.09           | 3,486.77         | 3,112.67         | 10,778.80          | 9,447.81           | 12,616.09          |
|        | (f) Other expenses  | 15,070.90          | 15,979.63        | 13,866.21        | 45,358.97          | 40,785.59          | 55,324.27          |
|        | <b>Total expenses</b>   | <b>84,384.80</b>   | <b>82,114.32</b> | <b>73,182.23</b> | <b>2,42,872.61</b> | <b>1,99,373.76</b> | <b>2,73,630.09</b> |
| 5      | <b>Profit before tax (3-4)</b>                                    | <b>18,761.49</b>   | <b>14,618.45</b> | <b>16,274.14</b> | <b>49,596.99</b>   | <b>34,508.17</b>   | <b>51,964.57</b>   |
| 6      | <b>Tax expense</b>  |                    |                  |                  |                    |                    |                    |
|        | a) Current tax  | 5,019.28           | 3,910.88         | 4,212.86         | 12,875.94          | 8,933.07           | 13,350.68          |
|        | b) Deferred tax   | (237.73)           | (185.25)         | (71.66)          | (628.48)           | (151.96)           | (37.59)            |
|        | <b>Total tax expense</b>  | <b>4,781.55</b>    | <b>3,725.63</b>  | <b>4,141.20</b>  | <b>12,247.46</b>   | <b>8,781.11</b>    | <b>13,313.09</b>   |
| 7      | <b>Profit for the period (5-6)</b>                                | <b>13,979.94</b>   | <b>10,892.82</b> | <b>12,132.94</b> | <b>37,349.53</b>   | <b>25,727.06</b>   | <b>38,651.48</b>   |
| 8      | <b>Other comprehensive income (net of tax)</b>                    |                    |                  |                  |                    |                    |                    |
|        | (a) (i) items that will not be reclassified to profit or loss     | -                  | -                | -                | -                  | -                  | (104.35)           |
|        | (ii) income tax on (i) above                                      | -                  | -                | -                | -                  | -                  | 26.26              |
|        | (b) (i) items that will be reclassified to profit or loss         | (3,011.98)         | 1,037.90         | 500.51           | (1,673.50)         | 1,189.30           | 1,913.86           |
|        | (ii) income tax on (i) above                                      | 758.06             | (261.22)         | (125.97)         | 421.19             | (299.32)           | (481.68)           |
|        | <b>Total other comprehensive income, net of tax</b>               | <b>(2,253.92)</b>  | <b>776.68</b>    | <b>374.54</b>    | <b>(1,252.31)</b>  | <b>889.98</b>      | <b>1,354.09</b>    |
| 9      | <b>Total comprehensive income (7+8)</b>                           | <b>11,726.02</b>   | <b>11,669.50</b> | <b>12,507.48</b> | <b>36,097.22</b>   | <b>26,617.04</b>   | <b>40,005.57</b>   |
| 10     | Paid-up equity share capital (Face Value of Rs. 1/- per share)    | 2,420.43           | 2,482.93         | 2,480.06         | 2,420.43           | 2,480.06           | 2,480.06           |
| 11     | Other equity  |                    |                  |                  |                    |                    | 2,50,586.05        |
| 12     | Earnings per share (Face value Rs. 1/- each)                      |                    |                  |                  |                    |                    |                    |
|        | (a) Basic (in Rs.)  | 5.75               | 4.39             | 4.89             | 15.15              | 10.38              | 15.60              |
|        | (b) Diluted (in Rs.)  | 5.74               | 4.37             | 4.88             | 15.13              | 10.34              | 15.55              |
|        |   | (Not annualised)   | (Not annualised) | (Not annualised) | (Not annualised)   | (Not annualised)   | (Annualised)       |


**Notes:**

- The above un-audited standalone financial results for the quarter and nine months ended December 31, 2022 have been reviewed by the Audit Committee on January 23, 2023 and approved by the Board of Directors at their meeting held on January 24, 2023.
- The un-audited standalone financial results of the Granules India Limited ("Company") have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- During the quarter ended December 31, 2022, the Company has concluded the buyback of 6,250,000 equity shares at a price of ₹ 400 per equity share ("Buyback") as approved earlier by the Board of Directors at their meeting held on August 09, 2022.
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2022.
- The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- The figures for the corresponding previous periods have been restated/regruoped wherever necessary, to make them comparable.

Place : Hyderabad  
 Date : January 24, 2023



for and on behalf of the Board





**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Granules India Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Granules India Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
  - Granules USA Inc
  - Granules Pharmaceuticals Inc.
  - Granules Consumer Health Inc.
  - Granules Europe Limited
  - Granules Life Sciences Private Limited




5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- 3 subsidiaries, whose unaudited interim financial results include total revenues of Rs. 47,815.26 Lakhs and Rs 1,49,392.69 Lakhs, total net profit after tax of Rs. (332.83) Lakhs and Rs. 2,359.94 Lakhs, total comprehensive income of Rs. 1,012.01 Lakhs and Rs. 9,093.34 Lakhs, for the quarter ended December 31, 2022 and nine months ended as on that date respectively as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information in respect of:
- 2 subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs. 430.21 Lakhs and Rs. 1,493.67 Lakhs, total net profit after tax of Rs. 193.56 Lakhs and Rs. 1,178.34 Lakhs, total comprehensive income of Rs. 200.35 Lakhs and Rs. 1,235.11 Lakhs, for the quarter ended December 31, 2022 and nine months ended as on that date respectively.

The unaudited interim financial results and other unaudited financial information of the these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

8. The comparative Ind AS financial information of the Group for the corresponding quarter and nine months ended December 31, 2021, included in these consolidated Ind AS financial results, were reviewed by the predecessor auditor and the Ind AS consolidated financial statements of the Group for the year ended March 31, 2022, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those consolidated financial information on February 08, 2022 and May 18, 2022 respectively.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

**ICAI Firm registration number: 101049W/E300004**

*Namul Kasi*

per Navneet Kabra

Partner

Membership No.: 102328



UDIN: **2310232866SBK9970**

Place: Hyderabad

Date: January 24, 2023



**GRANULES INDIA LIMITED**  
 Regd Office : 2nd Floor, 3rd Block, My Home Hub  
 Madhapur, Hyderabad 500 081  
 CIN:L24110TG1991PLC012471

Rs in lakhs


**Statement of Un-Audited Consolidated Results for the quarter and nine months ended December 31, 2022**

| Sl No. | Particulars   | Quarter ended      |                    |                    | Nine months ended  |                    | Year ended         |
|--------|---|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
|        |   | 31-Dec-22          | 30-Sep-22          | 31-Dec-21          | 31-Dec-22          | 31-Dec-21          | 31-Mar-22          |
|        |   | Un-Audited         | Un-Audited         | Un-Audited         | Un-Audited         | Un-Audited         | Audited            |
|        | <b>Income</b>   |                    |                    |                    |                    |                    |                    |
| 1      | Revenue from operations   | 1,14,612.68        | 1,15,073.43        | 99,676.99          | 3,31,641.67        | 2,73,494.74        | 3,76,492.10        |
| 2      | Other income  | 94.59              | 478.97             | 486.77             | 1,040.25           | 1,364.73           | 1,760.80           |
| 3      | <b>Total income (1+2)</b>   | <b>1,14,707.27</b> | <b>1,15,552.40</b> | <b>1,00,163.76</b> | <b>3,32,681.92</b> | <b>2,74,859.47</b> | <b>3,78,252.90</b> |
| 4      | <b>Expenses</b>   |                    |                    |                    |                    |                    |                    |
|        | (a) Cost of materials consumed                                    | 59,358.13          | 61,811.50          | 56,004.91          | 1,74,865.70        | 1,48,057.48        | 2,03,642.00        |
|        | (b) Changes in inventories of work in progress and finished goods | (182.80)           | (3,960.67)         | (2,812.20)         | (6,484.73)         | (12,298.75)        | (15,277.91)        |
|        | (c) Employee benefit expenses                                     | 11,915.03          | 11,771.20          | 10,531.45          | 34,558.33          | 29,322.02          | 40,137.69          |
|        | (d) Finance costs   | 1,697.40           | 1,322.18           | 459.30             | 3,713.27           | 1,684.92           | 2,321.07           |
|        | (e) Depreciation and amortisation expense                         | 4,836.39           | 4,406.22           | 3,922.92           | 13,578.89          | 11,845.15          | 15,863.20          |
|        | (f) Other expenses  | 20,393.02          | 21,160.57          | 18,579.39          | 60,131.92          | 55,460.53          | 75,767.02          |
|        | <b>Total expenses</b>   | <b>98,017.17</b>   | <b>96,511.00</b>   | <b>86,685.77</b>   | <b>2,80,363.38</b> | <b>2,34,071.35</b> | <b>3,22,453.07</b> |
| 5      | <b>Profit before tax (3-4)</b>                                    | <b>16,690.10</b>   | <b>19,041.40</b>   | <b>13,477.99</b>   | <b>52,318.54</b>   | <b>40,788.12</b>   | <b>55,799.83</b>   |
| 6      | <b>Tax expense</b>  |                    |                    |                    |                    |                    |                    |
|        | a) Current tax  | 5,064.09           | 3,754.46           | 4,278.89           | 12,984.97          | 9,573.42           | 13,820.48          |
|        | b) Deferred tax   | (806.86)           | 777.44             | (888.96)           | (365.65)           | 1,038.58           | 703.54             |
|        | <b>Total tax expense</b>  | <b>4,257.23</b>    | <b>4,531.90</b>    | <b>3,389.93</b>    | <b>12,619.32</b>   | <b>10,612.00</b>   | <b>14,524.02</b>   |
| 7      | <b>Profit for the period (5-6)</b>                                | <b>12,432.87</b>   | <b>14,509.50</b>   | <b>10,088.06</b>   | <b>39,699.22</b>   | <b>30,176.12</b>   | <b>41,275.81</b>   |
| 8      | <b>Other comprehensive income (net of tax)</b>                    |                    |                    |                    |                    |                    |                    |
|        | (a) (i) items that will not be reclassified to profit or loss     | -                  | -                  | -                  | -                  | -                  | (104.35)           |
|        | (ii) income tax on (i) above                                      | -                  | -                  | -                  | -                  | -                  | 26.26              |
|        | (b) (i) items that will be reclassified to profit or loss         | (1,660.35)         | 3,966.39           | 796.95             | 5,116.67           | 2,469.10           | 4,567.22           |
|        | (ii) income tax on (i) above                                      | 758.06             | (261.22)           | (125.97)           | 421.19             | (299.32)           | (481.68)           |
|        | <b>Total other comprehensive income, net of tax</b>               | <b>(902.29)</b>    | <b>3,705.17</b>    | <b>670.98</b>      | <b>5,537.86</b>    | <b>2,169.78</b>    | <b>4,007.45</b>    |
| 9      | <b>Total comprehensive income (7+8)</b>                           | <b>11,530.58</b>   | <b>18,214.67</b>   | <b>10,759.04</b>   | <b>45,237.08</b>   | <b>32,345.90</b>   | <b>45,283.26</b>   |
| 10     | <b>Profit for the period attributable to:</b>                     |                    |                    |                    |                    |                    |                    |
|        | (i) Equity shareholders of the Company                            | 12,432.87          | 14,509.50          | 10,088.06          | 39,699.22          | 30,176.12          | 41,275.79          |
|        | (ii) Non controlling interests                                    | -                  | -                  | -                  | -                  | -                  | 0.02               |
| 11     | <b>Total comprehensive income for the period attributable to:</b> |                    |                    |                    |                    |                    |                    |
|        | (i) Equity shareholders of the Company                            | 11,530.58          | 18,214.67          | 10,759.04          | 45,237.08          | 32,345.90          | 45,283.22          |
|        | (ii) Non controlling interests                                    | -                  | -                  | -                  | -                  | -                  | 0.04               |
| 12     | Paid-up equity share capital (Face Value of Rs. 1/- per share)    | 2,420.43           | 2,482.93           | 2,480.06           | 2,420.43           | 2,480.06           | 2,480.06           |
| 13     | Other equity excluding Non-controlling interest                   |                    |                    |                    |                    |                    | 2,56,173.23        |
| 14     | Earnings per share (Face value Rs. 1/- each)                      |                    |                    |                    |                    |                    |                    |
|        | (a) Basic (in Rs.)  | 5.11               | 5.85               | 4.07               | 16.10              | 12.18              | 16.66              |
|        | (b) Diluted (in Rs.)  | 5.10               | 5.82               | 4.05               | 16.08              | 12.12              | 16.60              |
|        |   | (Not annualised)   | (Not annualised)   | (Not annualised)   | (Not annualised)   | (Not annualised)   | (Annualised)       |

**Notes:**

- The above un-audited consolidated financial results for the quarter and nine months ended December 31, 2022 have been reviewed by the Audit Committee on January 23, 2023 and approved by the Board of Directors at their meeting held on January 24, 2023.
- The un-audited consolidated financial results of Granules India Limited ("Company") and its subsidiaries (together referred to as "Group") have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2022.
- The subsidiaries considered for the consolidation for the quarter ended December 31, 2022 are Granules USA Inc., Granules Pharmaceuticals Inc., Granules Europe Limited, Granules Life Sciences Private Limited and Granules Consumer Health, Inc. (Step-down subsidiary) (together referred to as "Subsidiaries").
- During the quarter ended December 31, 2022, the Company has concluded the buyback of 6,250,000 equity shares at a price of ₹ 400 per equity share ("Buyback") as approved earlier by the Board of Directors at their meeting held on August 09, 2022.
- The Group operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- The figures for the corresponding previous periods have been restated/regrouped wherever necessary, to make them comparable.

Place : Hyderabad  
 Date : January 24, 2023



for and on behalf of the Board  
  
 Dr. Krishna Prasad Chigurupati  
 Chairman and Managing Director  
 DIN : 00020180





**Press Release**

**for Immediate Release**

**Revenue from operations at INR 1,146 Cr up 15% YoY, EBITDA at INR 231 Cr up 275 bps YoY, PAT at INR 124 Cr up 23% YoY.**

**Hyderabad, India, January 24, 2023:** Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and nine months ended December 31, 2022.

**Financial Summary (All numbers in INR Cr., except Margins)**

| CONSOLIDATED FINANCIALS | Q3FY23 | Q2FY23 | Growth (QoQ) | Q3FY22 | Growth (YoY) |
|-------------------------|--------|--------|--------------|--------|--------------|
| Revenue from Operations | 1,146  | 1,151  | (0.4%)       | 997    | 15%          |
| EBITDA                  | 231    | 243    | (4.8%)       | 174    | 33%          |
| EBITDA %                | 20%    | 21%    |              | 17%    |              |
| PAT                     | 124    | 145    | (14%)        | 101    | 23%          |
| PAT %                   | 11%    | 13%    |              | 10%    |              |

**Financial and Business Summary for Q3FY23:**

- Revenue from Operations stood at INR 1,146 Cr, a growth of 15% YoY, primarily driven by higher Paracetamol API sales in the US. Revenue share from the USA increased to 49.4% in Q3 FY23 as compared to 43.1% YoY.
- Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 35.8%, 18.6%, and 45.6% of revenue from operations respectively.
- While Operating Cash flow is quite healthy at INR 161 Cr, Free cash flow at INR (32.5) Cr has got impacted due to additional deployment of INR 50 Cr in our new expansion plan with green initiatives in Kakinada and INR 42.5 Cr for land acquisition in Vishakhapatnam.
- ROCE increased to 25.6% as compared to 21.2% YoY.
- Net debt stood at INR 894 Cr vs INR 554 Cr in Q2FY23 and Net debt to EBITDA at 0.98x. Increase in Net debt is on account of reduction in cash due to buy back of shares and incremental capex for new initiatives.

**Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said,** “In the current quarter we continued to cater to higher demand for Paracetamol. Opportunities in Paracetamol are likely to continue and our geography expansion strategy in Europe is likely to yield higher turnover and EBITDA in future periods. We are also seeing a price and margin erosion in Q3 and expect similar trend in Q4.

*In the current quarter we had changed our 3PL partner in USA to a better partner who has better automation and digital capabilities. However, during the transition we have suffered some sales loss in USA and that is the reason for better standalone financial performance as compared to consolidated financial performance. We expect that smoothening of the logistics in USA could take a quarter more.*

*I am happy to see the progress of our EBITDA improvement plans and organization-wide movement towards Sustainability.”*

### **About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 7 manufacturing facilities out of which 6 are in India and 1 in the USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

### **Safe Harbor**

*This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.*

|   |  |
|---|--|
| <b>Contacts:</b>  |  |
| <b>Puneet Varshney</b><br>040-69043709<br>GM – Business Finance and Investor Relations<br>puneet.varshney@granulesindia.com | <b>Chaitanya Tummala</b><br>040-69043614<br>Company Secretary<br>chaitanya.tummala@granulesindia.com |